Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Clozapine and COVID-19: A Case Report and Clinical Considerations

Author(s): Dylan Lahiff, Peggy Chatham, Gregory Sullivan and Adam J. Fusick*

Volume 17, Issue 4, 2022

Published on: 01 March, 2022

Page: [382 - 386] Pages: 5

DOI: 10.2174/1574886316666211130142624

Price: $65

Abstract

Background: The emergence of coronavirus SARS-CoV-2, and the subsequent global epidemic of COVID-19, brought with it innumerable new clinical experiences across all medical specialties, and psychiatry is no exception. Individuals with serious mental illness, in particular schizophrenia and related disorders, may be especially susceptible to coronavirus infection given the overlapping risk factors of vulnerable sociodemographic status, increased challenges with quarantining requirements, and limited compliance with “respiratory etiquette.” The case presented here describes a patient with schizophrenia who was being managed on clozapine and who developed symptomatic COVID-19 infection. Special care was taken to ensure that potential interactions between clozapine and the associated COVID-19 treatments were safe for the patient’s mental and physical wellbeing.

Case Presentation: A 71-year-old schizophrenic Caucasian male is being managed with clozapine. While hospitalized, the patient was screened positive for COVID-19 and was admitted to the ICU due to his declining respiratory status. He was treated with both remdesivir and prednisone. He was able to fully recover from his COVID-19 infection.

Conclusion: The authors review the clinical characteristics of the case, highlighting both the overlapping synergistic effects and antagonistic influences of clozapine therapy in combination with COVID-19 and its associated treatments. A review of the literature offers an opportunity to examine various frameworks for individualized clinical decision-making while making the case for greater epidemiologic research into the optimal management of individuals with a psychotic disorder who are diagnosed with COVID-19 infection.

Keywords: COVID-19, remdesivir, clozapine, schizophrenia, corticosteroids, drug-drug interaction.

« Previous Next »
Graphical Abstract

[1]
Esakandari H, Nabi-Afjadi M, Fakkari-Afjadi J, Farahmandian N, Miresmaeili S-M, Bahreini E. A comprehensive review of COVID-19 characteristics. Biol Proced Online 2020; 22(1): 19.
[http://dx.doi.org/10.1186/s12575-020-00128-2] [PMID: 32774178]
[2]
Oliveira BA, Oliveira LC, Sabino EC, Okay TS. SARS-CoV-2 and the COVID-19 disease: A mini review on diagnostic methods. Rev Inst Med Trop São Paulo 2020; 62: e44.
[http://dx.doi.org/10.1590/s1678-9946202062044] [PMID: 32609256]
[3]
Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 2020; 109: 102433.
[http://dx.doi.org/10.1016/j.jaut.2020.102433] [PMID: 32113704]
[4]
Kozloff N, Mulsant BH, Stergiopoulos V, Voineskos AN. The COVID-19 global pandemic: Implications for people with schizophrenia and related disorders. Schizophr Bull 2020; 46(4): 752-7.
[http://dx.doi.org/10.1093/schbul/sbaa051] [PMID: 32343342]
[5]
Fonseca L, Diniz E, Mendonça G, Malinowski F, Mari J, Gadelha A. Schizophrenia and COVID-19: Risks and recommendations. Braz J Psychaitry 2020; 42(3): 236-8.
[http://dx.doi.org/10.1590/1516-4446-2020-0010] [PMID: 32294689]
[6]
Seminog OO, Goldacre MJ. Risk of pneumonia and pneumococcal disease in people with severe mental illness: English record linkage studies. Thorax 2013; 68(2): 171-6.
[http://dx.doi.org/10.1136/thoraxjnl-2012-202480] [PMID: 23242947]
[7]
Subramaniam M, Chong SA, Pek E. Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia. Can J Psychiatry 2003; 48(5): 345-7.
[http://dx.doi.org/10.1177/070674370304800512] [PMID: 12866342]
[8]
Haga T, Ito K, Sakashita K, Iguchi M, Ono M, Tatsumi K. Risk factors for pneumonia in patients with schizophrenia. Neuropsychopharmacol Rep 2018; 38(4): 204-9.
[http://dx.doi.org/10.1002/npr2.12034] [PMID: 30353691]
[9]
Dzahini O, Singh N, Taylor D, Haddad PM. Antipsychotic drug use and pneumonia: Systematic review and meta-analysis. J Psychopharmacol 2018; 32(11): 1167-81.
[http://dx.doi.org/10.1177/0269881118795333] [PMID: 30334664]
[10]
Raja M. Clozapine safety, 35 years later. Curr Drug Saf 2011; 6(3): 164-84.
[http://dx.doi.org/10.2174/157488611797579230] [PMID: 22122392]
[11]
Raja M, Raja S. Clozapine safety, 40 years later. Curr Drug Saf 2014; 9(3): 163-95.
[http://dx.doi.org/10.2174/1574886309666140428115040] [PMID: 24809463]
[12]
Silva E, Gee S, Smith S, Gaughran F. Clozapine and COVID-19. BJPsych Bull 2020; 44(4): 179-80.
[http://dx.doi.org/10.1192/bjb.2020.66] [PMID: 32718376]
[13]
Ponsford M, Castle D, Tahir T, et al. Clozapine is associated with secondary antibody deficiency. Br J Psychiatry 2018; 214(2): 1-7.
[PMID: 30259827]
[14]
Siskind D, Honer WG, Clark S, et al. Consensus statement on the use of clozapine during the COVID-19 pandemic. J Psychiatry Neurosci 2020; 45(4): 200061.
[PMID: 32242646]
[15]
Myles N, Myles H, Xia S, et al. Meta-analysis examining the epidemiology of clozapine-associated neutropenia. Acta Psychiatr Scand 2018; 138(2): 101-9.
[http://dx.doi.org/10.1111/acps.12898] [PMID: 29786829]
[16]
de Leon J, Sanz EJ, Norén GN, De Las Cuevas C. Pneumonia may be more frequent and have more fatal outcomes with clozapine than with other second-generation antipsychotics. World Psychiatry 2020; 19(1): 120-1.
[http://dx.doi.org/10.1002/wps.20707] [PMID: 31922665]
[17]
Govind R, Fonseca de Freitas D, Pritchard M, Hayes RD, MacCabe JH. Clozapine treatment and risk of COVID-19 infection: Retrospective cohort study. Br J Psychiatry 2020; 219(1): 1-7.
[http://dx.doi.org/10.1192/bjp.2020.151] [PMID: 32713374]
[18]
Clark SR, Warren NS, Kim G, et al. Elevated clozapine levels associated with infection: A systematic review. Schizophr Res 2018; 192: 50-6.
[http://dx.doi.org/10.1016/j.schres.2017.03.045] [PMID: 28392207]
[19]
Regen F, Herzog I, Hahn E, et al. Clozapine-induced agranulocytosis: Evidence for an immune-mediated mechanism from a patient-specific in-vitro approach. Toxicol Appl Pharmacol 2017; 316: 10-6.
[http://dx.doi.org/10.1016/j.taap.2016.12.003] [PMID: 27939987]
[20]
de Leon J, Ruan CJ, Verdoux H, Wang C. Clozapine is strongly associated with the risk of pneumonia and inflammation. Gen Psychiatr 2020; 33(2): e100183.
[http://dx.doi.org/10.1136/gpsych-2019-100183] [PMID: 32420521]
[21]
Cranshaw T, Harikumar T. COVID-19 infection may cause clozapine intoxication: Case report and discussion. Schizophr Bull 2020; 46(4): 751.
[http://dx.doi.org/10.1093/schbul/sbaa070] [PMID: 32435811]
[22]
Butler M, Bano F, Calcia M, et al. Clozapine prescribing in COVID-19 positive medical inpatients: A case series. Ther Adv Psychopharmacol 2020; 10: 2045125320959560.
[http://dx.doi.org/10.1177/2045125320959560] [PMID: 32974002]
[23]
COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health 2019. Available from: https://www.covid19treatmentguidelines.nih.gov (Accessed on: 11/19/2020).
[24]
Singh AK, Singh A, Singh R, Misra A. Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies. Diabetes Metab Syndr 2020; 14(4): 641-8.
[http://dx.doi.org/10.1016/j.dsx.2020.05.018] [PMID: 32428865]
[25]
University of Liverpool. COVID-19 drug interactions Available from: https://covid19-druginteractions.org (Accessed on: 11/25/2020).
[26]
Bishara D, Kalafatis C, Taylor D. Emerging and experimental treatments for COVID-19 and drug interactions with psychotropic agents. Ther Adv Psychopharmacol 2020; 10: 2045125320935306.
[http://dx.doi.org/10.1177/2045125320935306] [PMID: 32612804]
[27]
Plasencia-García BO, Rodríguez-Menéndez G, Rico-Rangel MI, Rubio-García A, Torelló-Iserte J, Crespo-Facorro B. Drug-drug interactions between COVID-19 treatments and antipsychotics drugs: integrated evidence from 4 databases and a systematic review. Psychopharmacology (Berl) 2021; 238(2): 329-40.
[http://dx.doi.org/10.1007/s00213-020-05716-4] [PMID: 33410987]
[28]
Sterne JAC, Murthy S, Diaz JV, et al. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of systemic corticosteroids and mortality among critically III patients with Covid-19: A meta-analysis. JAMA 2020; 324(13): 1330-41.
[http://dx.doi.org/10.1001/jama.2020.17023] [PMID: 32876694]
[29]
Ye Z, Wang Y, Colunga-Lozano LE, et al. Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: A systematic review and meta-analysis. CMAJ 2020; 192(27): E756-67.
[http://dx.doi.org/10.1503/cmaj.200645] [PMID: 32409522]
[30]
Kenna HA, Poon AW, de los Angeles CP, Koran LM. Psychiatric complications of treatment with corticosteroids: Review with case report. Psychiatry Clin Neurosci 2011; 65(6): 549-60.
[http://dx.doi.org/10.1111/j.1440-1819.2011.02260.x] [PMID: 22003987]
[31]
Manzo C, Serra-Mestres J, Castagna A, Isetta M. Behavioral, psychiatric, and cognitive adverse events in older persons treated with glucocorticoids. Medicines (Basel) 2018; 5(3): 82.
[http://dx.doi.org/10.3390/medicines5030082] [PMID: 30071590]
[32]
Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med 2020; 382(24): 2327-36.
[http://dx.doi.org/10.1056/NEJMoa2007016] [PMID: 32275812]
[33]
Gulati G, Kelly BD. Does remdesivir have any neuropsychiatric adverse effects? Ir J Psychol Med 2020; 38(4): 313-4.
[http://dx.doi.org/10.1017/ipm.2020.67] [PMID: 32641172]

Rights & Permissions Print Cite
Article Metrics
50
1
© 2024 Bentham Science Publishers | Privacy Policy